Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on October 27, 2016, to announce its third-quarter 2016 financial results. The primary purpose of this filing is to furnish the press release detailing these results, along with supplemental information available on the company's website. Investors should refer to the furnished press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) for a comprehensive understanding of the company's performance during the third quarter of 2016. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification and repository for these important disclosures. Investors seeking specific performance metrics, earnings per share, revenue figures, or guidance updates will need to consult the referenced exhibits. This filing indicates that BMY is meeting its disclosure obligations regarding quarterly financial reporting, providing investors with timely access to its operational and financial condition.
Key Highlights
- 1BMY filed an 8-K on October 27, 2016, announcing third-quarter 2016 financial results.
- 2The filing includes a press release (Exhibit 99.1) with the company's Q3 2016 financial results.
- 3Supplemental information related to the Q3 2016 results is also furnished (Exhibit 99.2).
- 4Investors are directed to these exhibits for detailed financial performance and operational data.
- 5The 8-K serves as an official notification of the company's quarterly financial reporting.
- 6This filing ensures timely access to important investor information as per SEC regulations.